New Vutrisiran Analyses Presented at the International Symposium on Amyloidosis (ISA) 2026

body

Analyses presented at ISA 2026 further support the impact of vutrisiran across the multisystemic manifestations of transthyretin-mediated amyloidosis (ATTR).

Sekijima, et al. “Treatment Effect of Vutrisiran on Measures of Polyneuropathy in HELIOS-B”
Witteles, et al. “Comparative Efficacy of Vutrisiran and Acoramidis in ATTR-CM: A Matching-Adjusted Indirect Comparison”
Mitter, et al. “Real-World Characteristics and Treatment Patterns Among New Vutrisiran Patients With ATTR-CM”
Costabel, et al. “Efficacy and Safety of Vutrisiran in South American Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post Hoc Analysis of HELIOS-B”
Mitter, et al. “Real-World Adherence and Persistence of Eplontersen in Patients with ATTR”

A post hoc analysis of HELIOS-B demonstrated statistically significant findings of vutrisiran versus placebo on neuropathy-related quality-of-life measures among patients with the cardiomyopathy of wild-type or hereditary ATTR (ATTR-CM) and evidence of polyneuropathy.

In an anchored matching-adjusted indirect comparison (MAIC), vutrisiran demonstrated nominally significant lower rates of all-cause mortality and cardiovascular hospitalization composites relative to acoramidis in patients with ATTR-CM.

Real-world data from more than 1,000 patients initiating vutrisiran demonstrated a higher prevalence of heart failure and greater comorbidity burden among second-line versus first-line initiators, supporting the rationale for initiating vutrisiran earlier in the treatment pathway. Additional presentations included a post hoc analysis of HELIOS-B in South American patients with ATTR-CM, and a real-world analysis of adherence and persistence with eplontersen in patients with ATTR.